Corifollitropin alfa

Drug Profile

Corifollitropin alfa

Alternative Names: Elonva; Follitropin-stimulating hormone long-acting; FSH long-acting; FSH-CTP; Long-acting follicle-stimulating hormone; MK-8962; ORG-36286; SCH-900962

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Organon
  • Developer Merck & Co
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility
  • Phase III Hypogonadism

Most Recent Events

  • 11 Jan 2017 Merck Sharp & Dohme plans a phase III trial for Hypogonadotropic hypogonadism (Combination therapy, In adolescents) in Russia (SC, Injection) (NCT03019575)
  • 02 Sep 2015 No recent reports on development identified - Phase-III for Female infertility in Canada (SC)
  • 30 Jun 2014 Merck receives complete response letter from the FDA for corifollitropin alfa in Female infertility in the second quarter of 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top